EVALUATION OF VITAMIN B12 LEVELS WITH NEUROPATHIC PAIN IN HEMODIALYSIS PATIENTS: A SINGLE CENTER OBSERVATIONAL STUDY
DOI:
https://doi.org/10.21776/ub.mnj.2024.010.02.03Keywords:
Vitamin B12, neuropathic pain, chronic kidney disease, hemodialysisAbstract
Background: Uremic syndrome in chronic kidney disease (CKD), particularly in hemodialysis (HD) patients, is a growing global health problem. The majority of patients with this condition experience one or more neurological disorders, such as neuropathic pain. One of the adjuvant therapies in the treatment of neuropathic pain is vitamin B12, which is important for the regeneration and myelination of peripheral nerves and also plays an important role in the restoration of functional nerves.
Objective: The aim of this research is to evaluate the role of vitamin B12 in the relief of pain symptoms
Method: This research was conducted at General Hospital in Bali use a case-control design and consecutive sampling. This was carried use 21 patients with CKD on regular hemodialysis with neuropathic pain, while 22 patients without neuropathic pain were used as the control group. All patients were tested for serum vitamin B12 levels. Neuropathic pain was assessed using the DN4.
Results: The data values of total vitamin B12 levels in blood serum were obtained within a range of 81.72 pmol/L to 2337.5 pmol/L, and a median value of 1306.25 pmol/L. A cut-off value of 1509.375 pmol/L was obtained with 76.2% sensitivity and 59.1% specificity. Furthermore, an odd ratio between low serum vitamin B12 and the incidence of neuropathic pain was also obtained, namely OR= 3.611 (95% CI= 1.012-12.9; p=0.044).
Conclusion: It was found that low serum vitamin B12 in CKD patients on hemodialysis increased the risk of experiencing neuropathic pain by 3.611 times compared to those with normal serum vitamin B12.
Downloads
References
Julian T, Syeed R, Glascow N, Angelopoulou E, Zis P. B12 as a treatment for peripheral neuropathic pain: A systematic review. Nutrients; 2020. 12(8):1–16. DOI: 10.3390/nu12082221
Ramírez BV, Gómez PAB. Uraemic neuropathy: A review. Int J Genet Mol Biol; 2011. 3(11):155–60.
Rizzo MA, Frediani F, Granata A, Ravasi B, Cusi D, Gallieni M. Neurological complications of hemodialysis: State of the art. J Nephrol; 2012. 25(2):170–82. DOI: 10.5301/jn.5000087
Duraisamy A, Parthasarathy P. Study on prevalence of peripheral neuropathy among patients on hemodialysis. IAIM; 2018. 5(10):73–80.
Ramachandran M, Subramanian V, Kuppusamy S, Parameswaran S, Chinnakali P, Vairappan B. The burden of peripheral neuropathy in nondiabetic chronic kidney disease and the role of ghrelin isoforms in its development. Indian J Nephrol; 2022. 32:567-73. DOI: 10.4103/ijn.IJN_557_20
Gondhali G, Kundalwal A, Takalkar AA. Peripheral neuropathy in Chronic Kidney Diseases: prevalence and its correlates. Int J Adv Med; 2019. 7(1):22.
Babu M, Kiran M, Ravindra K, Srinivas V, Kandregula P, Vardhan R, et al. Clinical manifestation and prevalence of peripheral neuropathy and nerve dysfunction in patients with chronic kidney disease. Int J Res Med Sci; 2015. 3(2):451.
Rivera JCH H, Gómez LF L, Sánchez R, Soto J G, JE RA, Menjivar C M, et al. Factors Related to the Presence of Anemia in Patients with Chronic Kidney Disease in Hemodialysis. Ann Hematol Oncol; 2021. 8(1).
Saifan C, Samarneh M, Shtaynberg N, Nasr R, El-Charabaty E, El-Sayegh S. Treatment of confirmed B12 deficiency in hemodialysis patients improves Epogen® requirements. Int J Nephrol Renovasc Dis; 2013. 6(March):89–93. DOI: 10.2147/IJNRD.S44660
Sil A, Kumar H, Mondal RD, Anand SS, Ghosal A, Datta A, et al. A randomized, open labeled study comparing the serum levels of cobalamin after three doses of 500 mcg vs. A single dose methylcobalamin of 1500 mcg in patients with peripheral neuropathy. Korean J Pain; 2018. 31(3):183–90.
Buesing S, Costa M, Schilling JM, Moeller-Bertram T. Vitamin B12 as a treatment for pain. Pain Physician; 2019. 22(1):E45–52.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 MNJ (Malang Neurology Journal)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
